{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:16:16Z","timestamp":1773872176368,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1097\/jcp.0b013e31822c09a7","type":"journal-article","created":{"date-parts":[[2011,10,4]],"date-time":"2011-10-04T20:04:12Z","timestamp":1317758652000},"page":"633-637","source":"Crossref","is-referenced-by-count":14,"title":["Comparing the Influence of Dopamine D2 Polymorphisms and Plasma Drug Concentrations on the Clinical Response to Risperidone"],"prefix":"10.1097","volume":"31","author":[{"given":"Norio","family":"Yasui-Furukori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoko","family":"Tsuchimine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manabu","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunao","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-14-20210128","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/00008571-200006000-00007","article-title":"The relationship between dopamine D2 receptor polymorphism at the Taq1A locus and therapeutic response to nemonapride, a selective dopamine antagonist, in schizophrenic patients.","volume":"10","author":"Suzuki","year":"2000","journal-title":"Pharmacogenetics"},{"key":"R3-14-20210128","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1176\/appi.ajp.158.5.802","article-title":"Association of short-term response to haloperidol treatment with a polymorphism in the dopamine D2 receptor gene.","volume":"158","author":"Schafer","year":"2001","journal-title":"Am J Psychiatry"},{"key":"R4-14-20210128","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00008571-200108000-00009","article-title":"The 141C Ins\/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients.","volume":"11","author":"Suzuki","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R5-14-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2004.11.014","article-title":"Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients.","volume":"376","author":"Wu","year":"2005","journal-title":"Neurosci Lett"},{"key":"R6-14-20210128","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1176\/appi.ajp.163.3.529","article-title":"DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients.","volume":"163","author":"Lencz","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R7-14-20210128","first-page":"92","article-title":"Allelic variation in the promoter region of the dopamine D2 receptor gene and clozapine response.","volume":"36","author":"Malhotra","year":"1999","journal-title":"Schizophr Res"},{"key":"R8-14-20210128","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/S0278-5846(03)00151-9","article-title":"Combination of dopamine D2 receptor gene polymorphisms as a possible predictor of treatmentresistance to dopamine antagonists in schizophrenic patients.","volume":"27","author":"Kondo","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R9-14-20210128","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/sj.tpj.6500211","article-title":"Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone.","volume":"3","author":"Yamanouchi","year":"2003","journal-title":"Pharmacogenomics J"},{"key":"R10-14-20210128","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2217\/14622416.9.10.1437","article-title":"Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia.","volume":"9","author":"Ikeda","year":"2008","journal-title":"Pharmacogenomics"},{"key":"R11-14-20210128","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-3565(25)24408-1","article-title":"Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.","volume":"244","author":"Jansen","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"key":"R12-14-20210128","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S0022-3565(25)13416-2","article-title":"Biochemical profile of risperidone, a new antipsychotic.","volume":"247","author":"Leysen","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"R13-14-20210128","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0090-9556(25)08211-X","article-title":"Absorption, metabolism, and excretion of risperidone in humans.","volume":"21","author":"Mannens","year":"1993","journal-title":"Drug Metab Dispos"},{"key":"R14-14-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF02246543","article-title":"Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man.","volume":"122","author":"Snoeck","year":"1995","journal-title":"Psychopharmacology"},{"key":"R15-14-20210128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/BF02245444","article-title":"The regional brain distribution of risperidone and its active metabolite 9-hydroxyrisperidone in the rat.","volume":"114","author":"Van Beijsterveldt","year":"1993","journal-title":"Psychopharmacology"},{"key":"R16-14-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","article-title":"Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.","volume":"54","author":"Huang","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"R17-14-20210128","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1177\/0269881109104849","article-title":"Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients.","volume":"24","author":"Yasui-Furukori","year":"2010","journal-title":"J Psychopharmacol"},{"key":"R18-14-20210128","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s002130000576","article-title":"Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia.","volume":"153","author":"Spina","year":"2001","journal-title":"Psychopharmacology"},{"key":"R19-14-20210128","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000054932","article-title":"Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Preliminary study.","volume":"44","author":"Yoshimura","year":"2001","journal-title":"Neuropsychobiology"},{"key":"R20-14-20210128","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00004850-200503000-00002","article-title":"Prediction of response to risperidone treatment with respect to plasma concencentrations of risperidone, catecholamine metabolites, and polymorphism of cytochrome P450 2D6.","volume":"20","author":"Kakihara","year":"2005","journal-title":"Int Clin Psychopharmacol"},{"key":"R21-14-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00406-004-0556-4","article-title":"Risperidone plasma levels, clinical response and side-effects.","volume":"255","author":"Riedel","year":"2005","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"suppl 326","key":"R22-14-20210128","first-page":"1S","article-title":"Mini-compendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes.","volume":"73","author":"Bech","year":"1986","journal-title":"Acta Psychiatr Scand"},{"issue":"suppl","key":"R23-14-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU Side Effect Rating Scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand"},{"key":"R24-14-20210128","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1159\/000284896","article-title":"Psychopathology of schizophrenia: initial validation of a 5-factor model.","volume":"28","author":"Lindenmayer","year":"1995","journal-title":"Psychopathology"},{"issue":"suppl 3","key":"R25-14-20210128","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1016\/0893-133X(95)00200-W","article-title":"Psychobiologic correlates of treatment response in schizophrenia.","volume":"14","author":"Lieberman","year":"1996","journal-title":"Neuropsychopharmacology"},{"issue":"suppl 9","key":"R26-14-20210128","first-page":"5","article-title":"Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia.","volume":"57","author":"Lieberman","year":"1996","journal-title":"J Clin Psychiatry"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004714-201110000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T12:43:36Z","timestamp":1741783416000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201110000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e31822c09a7","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}